biotechnicalcurrency.blogspot.com
Biotechnical Currency: Targanta Therapeutics Part I : Antimicrobial Resistance
http://biotechnicalcurrency.blogspot.com/2007/12/targanta-therapeutics-part-i.html
Saturday, December 15, 2007. Targanta Therapeutics Part I : Antimicrobial Resistance. Filed for an IPO in early October 2007. They are a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for serious infections. Their important therapeutic in development is oritavancin. A novel semi-synthetic glycopeptide. The evolution of increasingly antimicrobial-resistant bacterial species stems from a multitude of factors. Is perhaps the pathogen of greatest concern.
calinplesa.com
What happened to our dreams of phage? | Calin Plesa
http://www.calinplesa.com/what-happened-to-our-dreams-of-phage
2007: Bimetallic Thermal Resists. 2007: Wireless Handheld Gyroscopic Input Device. 2009: A Novel Cell-to-Cell Communication System. 2009: Noise Reduction in SQUIDs. 2008: BASc: polymer MEMS characterization. 2010: MSc: Two-Dimensional DNA Nanostructures. 2015: PhD: Solid state nanopores. Ubuntu / Vista dual boot installation on a Sony VGN-FZ. Thoughts on Books #3 →. What happened to our dreams of phage? December 5, 2008. I will not go into the details. First it must be realized that a phage is VERY speci...
biotechnicalcurrency.blogspot.com
Biotechnical Currency: December 2007
http://biotechnicalcurrency.blogspot.com/2007_12_01_archive.html
Saturday, December 15, 2007. Targanta Therapeutics Part I : Antimicrobial Resistance. Filed for an IPO in early October 2007. They are a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for serious infections. Their important therapeutic in development is oritavancin. A novel semi-synthetic glycopeptide. The evolution of increasingly antimicrobial-resistant bacterial species stems from a multitude of factors. Is perhaps the pathogen of greatest concern.
SOCIAL ENGAGEMENT